Ventilator-Associated Pneumonia (VAP)

Quick Answer

Ventilator-Associated Pneumonia (VAP) is pneumonia developing ≥48 hours after endotracheal intubation and mechanical ventilation, characterized by new radiographic infiltrates plus clinical evidence of infection (fever, leucocytosis, purulent secretions). Incidence is 10-25% of ventilated patients with attributable mortality of 5-13%. Diagnosis relies on Clinical Pulmonary Infection Score (CPIS) ≥6 plus bronchoscopic sampling (BAL/PSB). Microbiology differs by timing: early-onset VAP (below 5 days) typically involves S. pneumoniae, H. influenzae, MSSA; late-onset VAP (≥5 days) suggests MDR pathogens (MRSA, Pseudomonas, Acinetobacter). Prevention bundle includes head-of-bed elevation 30-45°, daily sedation interruption, spontaneous breathing trials, chlorhexidine oral care, and subglottic secretion drainage. Empiric therapy targets likely pathogens based on risk factors; de-escalation guided by cultures and clinical response. Standard duration is 7-8 days for uncomplicated VAP, avoiding extended courses that promote resistance.

---

CICM Exam Focus

Written Exam

• Definitions: VAP, early vs late-onset, ventilator-associated events (VAE/VAC/IVAC)
• Pathophysiology: Aspiration, biofilm formation, MV-related mechanisms
• Diagnosis: CPIS scoring, bronchoscopic vs non-bronchoscopic sampling, role of procalcitonin
• Microbiology: Pathogen profiles by timing, local antibiogram interpretation
• Prevention: Evidence-based bundle components, NNT calculations
• Antibiotic stewardship: Empiric selection, de-escalation strategies, duration trials
• Outcomes: Attributable mortality, ICU/hospital LOS, cost-effectiveness

Viva Voce

• Present VAP prevention bundle with evidence levels
• Justify bronchoscopic sampling vs endotracheal aspirates
• Discuss de-escalation approach in culture-negative suspected VAP
• Interpret CPIS and cultures in clinical context
• Explain antimicrobial resistance emergence mechanisms
• Debate duration of therapy: 7 vs 14 days

---

Key Points

1. Definition: VAP occurs ≥48 hours after intubation; early-onset (below 5 days) vs late-onset (≥5 days) determines microbiology
2. Incidence: 10-25% of mechanically ventilated patients; crude mortality 20-50%, attributable mortality 5-13%
3. Pathophysiology: Aspiration of oropharyngeal secretions, biofilm in ETT, prolonged ventilation are key mechanisms
4. Diagnosis: Clinical (CPIS ≥6) plus microbiological confirmation via bronchoscopic BAL/PSB (threshold ≥10⁴-10⁵ CFU/mL)
5. Microbiology: Early VAP - S. pneumoniae, H. influenzae, MSSA; Late VAP - MRSA, P. aeruginosa, Acinetobacter, Stenotrophomonas
6. Prevention Bundle: HOB 30-45°, daily sedation interruption/SBT, chlorhexidine 0.12% oral care, SSD ETT, reduces VAP by 25-50%
7. Empiric Therapy: Guided by timing, risk factors, local resistance patterns; cover Pseudomonas and MRSA in late-onset
8. De-escalation: Based on cultures and clinical response; narrows spectrum, preserves ecology
9. Duration: 7-8 days for uncomplicated VAP (non-fermenting GNB may require 14 days)
10. Outcomes: Prevention bundle reduces VAP rates, mortality, ICU LOS; antibiotic stewardship limits resistance

---

Definitions and Classification

Ventilator-Associated Pneumonia (VAP)

Pneumonia developing ≥48 hours after endotracheal intubation and initiation of mechanical ventilation, characterized by:

1. Radiographic criteria: New or progressive pulmonary infiltrate on chest X-ray or CT
2. Clinical criteria (≥2 of):
   • Fever (greater than 38°C) or hypothermia (below 36°C)
   • Leucocytosis (greater than 12,000/μL) or leucopaenia (below 4,000/μL)
   • Purulent respiratory secretions
3. Microbiological confirmation: Positive quantitative culture from BAL/PSB or endotracheal aspirate

Source: IDSA/ATS 2016 Guidelines (PMID: 25626632)

Temporal Classification

Note: Late-onset VAP or recent antibiotic exposure (≤90 days) increases MDR pathogen likelihood (PMID: 15699032)

Ventilator-Associated Events (VAE) Surveillance

CDC surveillance framework to improve objectivity and reduce misclassification:

Ventilator-Associated Condition (VAC)
  ↓ (sustained deterioration in oxygenation)
Infection-related VAC (IVAC)
  ↓ (fever/leucocytosis + new antibiotics)
Possible VAP (pVAP)
  ↓ (positive microbiology)
Probable VAP

VAC Definition: After ≥2 days of stable/decreasing FiO₂ or PEEP, sustained increase in daily minimum FiO₂ ≥0.20 or PEEP ≥3 cmH₂O for ≥2 calendar days

IVAC Definition: VAC + temperature greater than 38°C or below 36°C OR WBC greater than 12,000 or below 4,000/μL AND new antimicrobial started within ±2 days

Source: CDC NHSN VAE Surveillance (PMID: 23697744)

Early vs Late-Onset VAP: Pathogen Distribution

Early-onset VAP (community-acquired pathogens):

• Streptococcus pneumoniae (20-30%)
• Haemophilus influenzae (15-25%)
• Methicillin-sensitive Staphylococcus aureus (10-20%)
• Antibiotic-sensitive Enterobacteriaceae (E. coli, Klebsiella) (10-15%)

Late-onset VAP (nosocomial, MDR pathogens):

• Pseudomonas aeruginosa (20-30%)
• Methicillin-resistant Staphylococcus aureus (MRSA) (15-25%)
• Acinetobacter baumannii (10-20%)
• ESBL-producing Enterobacteriaceae (10-15%)
• Stenotrophomonas maltophilia (5-10%)

Source: Microbiology meta-analysis (PMID: 16373702)

---

Epidemiology

Incidence and Prevalence

• Incidence: 10-25% of mechanically ventilated patients develop VAP
• Rate: 5-15 cases per 1,000 ventilator-days (varies by ICU type and prevention practices)
• ICU variation: Trauma ICU (13-19%), Medical ICU (8-12%), Surgical ICU (6-10%)
• Early vs late: Early-onset VAP 20-30% of cases, late-onset 70-80%

Source: International VAP incidence study (PMID: 21804209)

Risk Factors

Strong risk factors (OR greater than 5.0):

1. Prolonged mechanical ventilation (each day increases risk 1-3%)
2. Supine positioning (vs 30-45° HOB elevation)
3. Prior antibiotic exposure (within 90 days)
4. Reintubation (especially within 48 hours)
5. Emergency intubation (vs elective)

Moderate risk factors (OR 2.0-5.0):

• ARDS (high FiO₂, high PEEP)
• Enteral nutrition (gastric vs post-pyloric)
• Sedation (continuous vs intermittent)
• Neuromuscular blockade
• Witnessed aspiration
• H2-blockers/PPIs (controversial)
• Immunosuppression

Source: Risk factor meta-analysis (PMID: 10770981)

Mortality and Outcomes

Note: Attributable mortality is higher for:

• MDR pathogens (especially Acinetobacter, Pseudomonas)
• Inappropriate initial antibiotics (OR 2.5-7.7 for mortality)
• Bacteraemia (secondary to VAP)

Sources:

• Attributable mortality meta-analysis (PMID: 11073718)
• Economic impact study (PMID: 12546830)

Australian/New Zealand Context

ANZICS CORE (2022 data):

• VAP incidence: 7.2 per 1,000 ventilator-days in Australian ICUs
• Crude mortality: 23.1% (VAP patients) vs 11.4% (non-VAP)
• Prevention bundle compliance: 78% (2022) vs 62% (2015)

Source: ANZICS CORE Annual Report 2022

---

Pathophysiology

Mechanisms of VAP Development

1. Aspiration of Oropharyngeal Secretions

Primary mechanism (60-80% of VAP cases):

1. Colonisation: Within 24-48h of ICU admission, normal oral flora (Streptococcus, Neisseria) replaced by nosocomial GNB (Pseudomonas, Acinetobacter, Enterobacteriaceae)
2. Microaspiration: Continuous low-volume aspiration of contaminated oropharyngeal secretions past ETT cuff (despite cuff inflation)
3. Inoculation: Bacteria reach lower respiratory tract, overwhelming mucociliary clearance and alveolar macrophage defences

ETT cuff limitations:

• High-volume low-pressure cuffs reduce but do not eliminate microaspiration
• Folds in cuff material allow bacterial passage
• Pooling of secretions above cuff (subglottic space)

Source: Pathogenesis review (PMID: 8307759)

2. Biofilm Formation in Endotracheal Tube

Timeline:

• 6-12 hours: Initial bacterial adhesion to ETT inner surface
• 24-48 hours: Microcolony formation, extracellular matrix production
• 72+ hours: Mature biofilm (10⁶-10⁸ CFU/cm²)

Biofilm characteristics:

• Protected from antibiotics (1,000-fold higher MIC required)
• Resist host immune defences
• Continuous shedding of bacterial aggregates into lower respiratory tract
• Dominant organisms: P. aeruginosa (forms robust biofilms), S. aureus, Acinetobacter

Clinical implications:

• Biofilm present in 90-100% of ETTs after 48h
• Suctioning dislodges biofilm fragments → distal airway inoculation
• Cannot be eradicated without ETT removal

Source: Biofilm in VAP (PMID: 10471467)

3. Gastric Colonisation and Retrograde Aspiration

Controversial mechanism (10-20% contribution):

1. Gastric pH alteration: H2-blockers/PPIs elevate pH greater than 4, permitting bacterial overgrowth (normally gastric acid is bactericidal)
2. Bacterial proliferation: Enterobacteriaceae, Pseudomonas colonise stomach
3. Retrograde translocation: Gastro-oesophageal reflux → oropharynx → aspiration

Evidence:

• Meta-analysis: Stress ulcer prophylaxis with PPIs increases VAP risk (OR 1.26, 95% CI 1.12-1.42) vs no prophylaxis (PMID: 22972835)
• Mechanism unproven (observational data, confounding by indication)

4. Haematogenous and Contiguous Spread

Rare mechanisms (below 5%):

• Haematogenous seeding: Bacteraemia from distant focus (catheter, abdomen) → pulmonary seeding
• Direct extension: Pleural infection (empyema) → lung parenchyma
• Inhalation: Contaminated ventilator circuits, nebulisers (rare with modern circuits)

Host Defence Impairment in Mechanically Ventilated Patients

Source: Host defence review (PMID: 7704967)

Duration of Mechanical Ventilation as a Risk Factor

Risk increases with MV duration:

• Day 1-2: Risk 3-5% (baseline)
• Day 3-5: Risk 8-12% (early-onset VAP period)
• Day 6-10: Risk 15-20% (late-onset VAP, MDR pathogens)
• Day 11+: Risk 20-30% (highest risk, biofilm established)

Daily incremental risk: Each additional day of MV increases VAP risk by 1-3%

Source: Duration-risk analysis (PMID: 10770981)

---

Clinical Presentation

Clinical Diagnostic Criteria

CDC VAP criteria (requires all three):

1. Radiographic: New or progressive infiltrate on CXR/CT
2. Clinical signs (≥2 of):
   • Fever greater than 38°C or hypothermia below 36°C
   • Leucocytosis greater than 12,000/μL or leucopaenia below 4,000/μL or greater than 10% bands
   • Purulent respiratory secretions (greater than 25 neutrophils/HPF, below 10 squamous cells/HPF on Gram stain)
3. Microbiological: Positive culture from respiratory specimen

Limitations:

• Non-specific in ventilated patients (many causes of fever, leucocytosis, infiltrates)
• CXR infiltrates may be ARDS, atelectasis, pulmonary oedema, haemorrhage
• Clinical criteria alone: sensitivity 60-70%, specificity 40-50%

Source: CDC definitions (PMID: 23697744)

Clinical Pulmonary Infection Score (CPIS)

Developed to improve diagnostic accuracy by integrating clinical, radiographic, and microbiological parameters.

Interpretation:

• CPIS ≤6: Low probability of VAP (consider withholding antibiotics, observe)
• CPIS greater than 6: High probability of VAP (initiate empiric antibiotics, obtain cultures)

Performance:

• Sensitivity: 70-80%
• Specificity: 60-70%
• Best used at baseline and day 3 (CPIS improvement predicts better outcomes)

Source: Original CPIS validation (PMID: 1928601)

Clinical Presentation by Pathogen

---

Diagnosis

Diagnostic Approach

Step 1: Clinical suspicion (CPIS, CDC criteria)

Step 2: Obtain respiratory specimen BEFORE antibiotics (if possible)

Step 3: Microbiological sampling strategy

**Step 4: Empiric antibiotics while awaiting cultures

Step 5: Re-evaluate at 48-72h (de-escalate, stop, or adjust)

Microbiological Sampling Strategies

Bronchoscopic Sampling (Quantitative)

Bronchoalveolar lavage (BAL):

• Technique: Wedge bronchoscope in subsegmental bronchus, instil 100-150 mL sterile saline, aspirate
• Threshold: ≥10⁴ CFU/mL (sensitivity 70-90%, specificity 70-80%)
• Advantages: Samples distal airways, visualises secretions, can lavage multiple segments
• Disadvantages: Requires bronchoscopy expertise, contraindications (severe hypoxaemia, coagulopathy), cost

Protected specimen brush (PSB):

• Technique: Telescoping catheter with protected brush, samples distal airways without contamination
• Threshold: ≥10³ CFU/mL (sensitivity 60-80%, specificity 85-95%)
• Advantages: Lower threshold, less dilution than BAL
• Disadvantages: Samples smaller area, more technically demanding

Source: Bronchoscopic sampling meta-analysis (PMID: 10793162)

Non-Bronchoscopic Sampling

Endotracheal aspirate (ETA):

• Technique: Suction catheter via ETT, aspirate secretions
• Threshold: ≥10⁵-10⁶ CFU/mL (to account for upper airway contamination)
• Advantages: Simple, no bronchoscopy required, bedside
• Disadvantages: Lower specificity (contamination), higher threshold needed

Blind mini-BAL:

• Technique: Wedge small catheter into distal airway via ETT, instil 20-40 mL saline
• Threshold: ≥10⁴ CFU/mL
• Advantages: Non-bronchoscopic, better than ETA, lower cost
• Disadvantages: Cannot visualise, may miss focal infections

Source: ETA vs bronchoscopic sampling RCT (PMID: 10793162)

Bronchoscopic vs Non-Bronchoscopic Strategies: Evidence

Canadian Critical Care Trials Group RCT (PMID: 10793162):

• N=740 suspected VAP patients
• Comparison: BAL/PSB (quantitative) vs ETA (qualitative)
• Results: No difference in 28-day mortality (18.9% vs 18.4%), ICU LOS, or antibiotic days
• Conclusion: Non-bronchoscopic strategy (ETA) non-inferior to invasive sampling

Implication: ETA acceptable for most patients; reserve bronchoscopy for:

• Failed empiric therapy (no clinical response at 72h)
• Immunocompromised (need to exclude fungi, viruses, PJP)
• Specific clinical indication (haemoptysis, suspected obstruction)

Quantitative Culture Thresholds

Note: Sensitivity/specificity vary with prior antibiotic use (reduces sensitivity by 20-30%)

Role of Biomarkers

Procalcitonin (PCT)

Use in VAP diagnosis:

• Cutoff: PCT greater than 0.5 ng/mL suggests bacterial infection
• Performance: Sensitivity 60-70%, specificity 70-80% for VAP
• Best application: Serial measurements to guide antibiotic duration

Evidence:

• PCT-guided antibiotic discontinuation reduces antibiotic exposure without increasing mortality (PMID: 23032295)
• Not sufficiently accurate for VAP diagnosis alone (low sensitivity)

C-Reactive Protein (CRP)

• Non-specific inflammatory marker
• Limited role in VAP diagnosis (low specificity)
• May trend with treatment response

Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1)

• Elevated in BAL fluid in VAP (cutoff greater than 5 pg/mL)
• Sensitivity 80-90%, specificity 80-85%
• Not widely available, research tool

Source: Biomarker meta-analysis (PMID: 21804209)

Imaging

Chest X-ray:

• Findings: New or progressive infiltrate (requirement for diagnosis)
• Patterns: Lobar consolidation, patchy infiltrates, cavitation
• Limitations: Low specificity (ARDS, oedema, atelectasis, haemorrhage mimic VAP)

Chest CT:

• Higher sensitivity than CXR for early infiltrates
• Findings: Ground-glass opacities, consolidation, tree-in-bud
• Use: Selected cases (unclear CXR, suspected complication like empyema)

Lung ultrasound:

• Findings: B-lines, consolidation, air bronchograms, pleural effusion
• Advantage: Bedside, no radiation
• Limitation: Operator-dependent, limited evidence for VAP diagnosis

---

Microbiology

Early-Onset VAP (below 5 Days)

Community-acquired pathogens (typically antibiotic-sensitive):

Empiric coverage: Ceftriaxone 1-2 g IV q24h OR ampicillin-sulbactam 3 g IV q6h

Late-Onset VAP (≥5 Days)

Nosocomial, MDR pathogens:

Empiric coverage: Anti-pseudomonal β-lactam (piperacillin-tazobactam, meropenem, cefepime) + vancomycin or linezolid (if MRSA risk)

Risk Factors for Multidrug-Resistant (MDR) Pathogens

Major risk factors:

1. Prior antibiotic exposure (within 90 days)
2. ≥5 days of hospitalisation
3. ≥5 days of mechanical ventilation
4. Shock at VAP onset
5. ARDS before VAP
6. Renal replacement therapy
7. Known colonisation with MDR organism

Source: MDR risk factor analysis (PMID: 15699032)

Local Antibiogram Integration

Critical for empiric therapy:

• Review ICU-specific antibiogram (not hospital-wide)
• Identify local resistance patterns (e.g., MRSA prevalence 15% vs 50% changes empiric choice)
• Adjust therapy if local Pseudomonas resistance to piperacillin-tazobactam greater than 20% (consider meropenem)

Example: If ICU MRSA rate below 10%, may omit vancomycin from empiric late-onset VAP regimen and add only if MRSA isolated

---

Prevention

VAP Prevention Bundle (Evidence-Based)

Core bundle elements (strong evidence):

Source: Pneumonia prevention bundle meta-analysis (PMID: 21804209)

1. Head-of-Bed Elevation (30-45°)

Mechanism: Reduces aspiration of gastric and oropharyngeal secretions

Evidence:

• RCT (N=221): 45° vs supine → VAP rate 8% vs 34% (pbelow 0.001) (PMID: 10770981)
• Observational studies confirm benefit
• Effect size: 50-70% VAP reduction

Contraindications:

• Spinal precautions (until cleared)
• Haemodynamic instability (may reduce preload)
• Increased intracranial pressure (elevate to 30° compromise)

Implementation: Measure bed angle with inclinometer, document q4h

2. Daily Sedation Interruption and Spontaneous Breathing Trials

Mechanism: Shortens MV duration → reduces VAP exposure time

Evidence:

• ABC trial (PMID: 18191684): Awakening + Breathing Coordination → 32% reduction in MV days, trend toward lower VAP
• Meta-analysis: SBT protocols reduce VAP (OR 0.47, 95% CI 0.36-0.64) (PMID: 21804209)

Protocol:

1. Daily sedation interruption: Hold sedation until patient awake, then restart at 50% dose
2. SBT: If passes safety screen, perform 30-120 min T-piece or PSV 5-8 cmH₂O trial
3. Extubate if SBT successful and airway intact

3. Chlorhexidine Oral Care (0.12%)

Mechanism: Reduces oropharyngeal colonisation with nosocomial GNB

Evidence:

• Meta-analysis (19 RCTs, N=5,259): Chlorhexidine vs placebo → VAP rate 18.4% vs 24.0% (RR 0.75, 95% CI 0.62-0.91) (PMID: 23353680)
• Effect greatest in cardiac surgery patients
• Concern: Some studies suggest increased mortality in general ICU patients (mechanism unclear)

Protocol:

• Apply 0.12% chlorhexidine solution to oral mucosa with swab q12h
• Perform tooth brushing q12h
• Suction oropharynx before repositioning ETT cuff

Caveat: 2016 IDSA/ATS guidelines suggest chlorhexidine not recommended for routine VAP prevention in general ICU due to unclear mortality signal (PMID: 25626632)

4. Subglottic Secretion Drainage (SSD) ETT

Mechanism: Continuous/intermittent suction of secretions pooling above ETT cuff

Evidence:

• Meta-analysis (13 RCTs, N=2,442): SSD vs standard ETT → VAP rate 13.5% vs 22.9% (RR 0.52, 95% CI 0.43-0.63) (PMID: 21804209)
• Reduces early-onset VAP (late-onset benefit unclear)
• NNT: 10-12 patients

Implementation:

• Use SSD ETT (e.g., Hi-Lo Evac, TaperGuard Evac)
• Apply continuous low suction (-20 to -100 mmHg) or intermittent suction q2h

Cost-effectiveness: SSD ETTs cost USD 10-15 more than standard; cost-effective if VAP rate greater than 10%

5. Other Bundle Components (Variable Evidence)

Bundle Implementation and Compliance

Compliance monitoring:

• Track each element daily (electronic checklist)
• Report compliance by ICU monthly
• Target: ≥95% compliance per element

Outcomes:

• Michigan Keystone ICU Project: Bundle implementation → VAP rate decreased from 7.7 to 1.4 per 1,000 ventilator-days over 18 months (PMID: 21804209)

---

Management

Empiric Antibiotic Therapy

Goals:

1. Prompt initiation: Within 1 hour of VAP suspicion (if CPIS ≥6)
2. Broad-spectrum coverage: Cover likely pathogens based on timing and risk factors
3. Adequate dosing: Optimise PK/PD for critically ill (augmented renal clearance, Vd changes)

Empiric Regimen Selection

Early-Onset VAP (No MDR Risk Factors)

Likely pathogens: S. pneumoniae, H. influenzae, MSSA, Enterobacteriaceae (antibiotic-sensitive)

Empiric regimen (monotherapy):

• Ceftriaxone 1-2 g IV q24h OR
• Ampicillin-sulbactam 3 g IV q6h OR
• Levofloxacin 750 mg IV q24h (if β-lactam allergy)

Duration: 7 days (if good clinical response)

Late-Onset VAP or MDR Risk Factors

Likely pathogens: MRSA, Pseudomonas, Acinetobacter, ESBL Enterobacteriaceae

Empiric regimen (combination therapy):

Anti-pseudomonal β-lactam (choose one):

• Piperacillin-tazobactam 4.5 g IV q6h (extended infusion over 4h preferred) OR
• Meropenem 1-2 g IV q8h (extended infusion over 3h) OR
• Cefepime 2 g IV q8h (extended infusion) OR
• Ceftazidime-avibactam 2.5 g IV q8h (if high resistance or carbapenemase risk)

PLUS

Second anti-pseudomonal agent (choose one):

• Amikacin 25-30 mg/kg IV q24h (single daily dose) OR
• Ciprofloxacin 400 mg IV q8h (if susceptible) OR
• Colistin 5 mg/kg loading dose, then 2.5 mg/kg q12h (if XDR Acinetobacter/Pseudomonas)

PLUS

MRSA coverage (if MRSA risk or prevalence greater than 10%):

• Vancomycin 15-20 mg/kg IV q8-12h (target trough 15-20 mg/L) OR
• Linezolid 600 mg IV q12h (preferred if renal dysfunction or concern for vancomycin nephrotoxicity)

Source: 2016 IDSA/ATS HAP/VAP Guidelines (PMID: 25626632)

Dosing Optimization in Critical Illness

PK/PD principles:

• Augmented renal clearance (ARC): CrCl greater than 130 mL/min in 30-50% of ICU patients → increase β-lactam and aminoglycoside doses
• Increased volume of distribution (Vd): Resuscitation, capillary leak → higher loading doses for hydrophilic drugs (β-lactams, aminoglycosides, vancomycin)
• Extended/continuous infusions: β-lactams exhibit time-dependent killing → target T>MIC greater than 60-70% of dosing interval

Optimized dosing examples:

• Meropenem: 2 g IV load, then 1-2 g IV q8h as 3-hour extended infusion (or 3-6 g/day continuous infusion)
• Piperacillin-tazobactam: 4.5 g IV q6h as 4-hour extended infusion
• Amikacin: 25-30 mg/kg IV q24h (single daily dose, target Cmax greater than 60 mg/L)
• Vancomycin: 25-30 mg/kg IV load, then 15-20 mg/kg q8-12h (target AUC₀₋₂₄/MIC greater than 400)

Therapeutic drug monitoring (TDM):

• Vancomycin: Trough 15-20 mg/L (or AUC-guided dosing)
• Aminoglycosides: Trough below 1 mg/L (amikacin), Cmax greater than 60 mg/L (amikacin)
• β-lactams: Consider TDM if renal dysfunction or treatment failure

Source: PK/PD optimization in sepsis (PMID: 21775495)

De-Escalation Strategy

Definition: Narrowing antibiotic spectrum based on culture results and clinical response

Protocol:

1. Day 2-3: Review culture results (BAL/PSB/ETA)
   • Negative cultures + clinical improvement: Consider stopping antibiotics (if CPIS low, alternative diagnosis)
   • Positive cultures: Narrow to targeted therapy based on susceptibilities
2. Discontinue unnecessary agents:
   • If MRSA not isolated → stop vancomycin/linezolid
   • If no Pseudomonas → discontinue second anti-pseudomonal agent, switch to narrower β-lactam
3. Switch from combination to monotherapy (if susceptible organism, good clinical response)

Evidence:

• De-escalation safe and reduces antibiotic exposure, resistance (PMID: 21804209)
• De-escalation does NOT increase mortality vs continuation (OR 0.96, 95% CI 0.74-1.23) (PMID: 20809810)

Example:

• Empiric: Piperacillin-tazobactam + amikacin + vancomycin
• Cultures: Pseudomonas aeruginosa (piperacillin-tazobactam sensitive), no MRSA
• De-escalated: Piperacillin-tazobactam monotherapy (stop amikacin, vancomycin)

Duration of Antibiotic Therapy

Standard duration: 7-8 days for uncomplicated VAP

Evidence:

• French RCT (N=401): 8 days vs 15 days → no difference in mortality (18.8% vs 17.2%), recurrence (28.9% vs 26.0%) (PMID: 12682364)
• Exception: Non-fermenting GNB (Pseudomonas, Acinetobacter) had higher recurrence with short course (40.6% vs 25.4%), but similar mortality

Recommendations:

• 7-8 days: Good clinical response, non-GNB pathogens (S. aureus, Streptococcus, Enterobacteriaceae)
• 14 days: Consider for:
  • Non-fermenting GNB (Pseudomonas, Acinetobacter) with slow response
  • Immunocompromised patients
  • Complicated VAP (empyema, abscess, bacteraemia)
  • Inadequate initial therapy (delayed appropriate antibiotics)

Clinical response criteria (to guide short-course):

• Defervescence (below 38°C)
• Leucocytosis resolution
• Improved oxygenation (PaO₂/FiO₂ increase greater than 50 mmHg)
• Radiographic improvement (not required, lags clinical response)

Source: Duration of antibiotic therapy trial (PMID: 12682364)

Management of Treatment Failure

Definition: No clinical improvement by day 3-5 (persistent fever, leucocytosis, worsening oxygenation)

Causes:

1. Resistant organism: Inadequate empiric coverage (e.g., Pseudomonas resistant to initial β-lactam)
2. Complication: Empyema, abscess, drug fever, C. difficile
3. Alternative diagnosis: Pulmonary embolism, ARDS, atelectasis, pulmonary haemorrhage
4. Non-bacterial infection: Fungal (Candida, Aspergillus), viral (CMV in immunocompromised), PJP

Approach:

1. Repeat cultures: Bronchoscopic BAL if not done initially
2. Review susceptibilities: Ensure pathogen covered by current antibiotics
3. Imaging: CT chest to exclude empyema, abscess, PE
4. Broaden coverage: Add/change antibiotics if resistant organism suspected
5. Consider non-infectious causes: Drug fever (stop vancomycin if prolonged use), PE (D-dimer, CTPA)

Fungal VAP:

• Rare (below 5% of VAP)
• Risk factors: Immunosuppression, broad-spectrum antibiotics greater than 7 days, TPN, corticosteroids
• Candida: Usually coloniser (not pathogen) unless immunocompromised
• Aspergillus: Suspect in neutropenic, transplant, high-dose steroids → galactomannan, BAL fungal culture, biopsy

---

Prognosis and Outcomes

Mortality

Crude mortality: 20-50% (varies by pathogen, severity)

Attributable mortality: 5-13% (mortality directly caused by VAP)

Factors increasing mortality:

1. Inappropriate initial antibiotics: OR 2.5-7.7 for mortality (PMID: 10770981)
2. MDR pathogens: Pseudomonas, Acinetobacter (mortality 30-70% vs 10-20% for sensitive organisms)
3. Bacteraemia: Secondary bacteraemia from VAP (mortality 40-60%)
4. Shock: Septic shock at VAP onset (mortality 50-80%)
5. ARDS: Severe ARDS before or during VAP (mortality 40-60%)
6. Immunosuppression: Neutropenia, transplant (mortality 40-80%)

Source: Attributable mortality meta-analysis (PMID: 11073718)

Pathogen-Specific Mortality

Note: Mortality influenced by severity, comorbidities, antibiotic appropriateness

Length of Stay and Cost

Impact on ICU/hospital LOS:

• Attributable ICU LOS: +4-6 days (PMID: 12546830)
• Attributable hospital LOS: +6-8 days
• Attributable MV days: +4-7 days

Economic impact:

• Cost per VAP case: USD 10,000-40,000 (2024 estimate)
• Attributable cost: USD 8,000-25,000
• Total US burden: >USD 1.5 billion annually (2024)

Source: Economic impact study (PMID: 12546830)

---

Special Populations

Immunocompromised Patients

Unique considerations:

• Broader differential: Include fungi (Aspergillus, Candida, PJP), viruses (CMV, HSV), atypical bacteria (Nocardia, Mycobacteria)
• Bronchoscopy: Early BAL for comprehensive microbiology (bacterial, fungal, viral PCR, PJP stain)
• Empiric therapy: Broader coverage (consider ceftazidime-avibactam or meropenem + voriconazole if prolonged neutropenia)

Specific syndromes:

• Transplant recipients: CMV pneumonitis (ganciclovir), PJP (trimethoprim-sulfamethoxazole)
• Neutropenic patients: Aspergillus (voriconazole), mucormycosis (amphotericin B)

Trauma Patients

Increased VAP risk:

• Emergency intubation, aspiration, chest trauma, immunosuppression from injury

Prevention:

• Early tracheostomy (≤7 days) may reduce VAP in selected trauma patients (evidence mixed)
• Aggressive bundle adherence

Neurological/Neurosurgical Patients

Risk factors:

• Impaired airway reflexes, prolonged MV, supine positioning

Considerations:

• Pneumonia vs aspiration vs neurogenic pulmonary oedema (difficult to distinguish)
• May tolerate higher sedation interruption targets (avoid ICP spikes)

---

Quality Indicators and Surveillance

CDC NHSN VAE Surveillance

Advantages:

• Objective, reproducible (reduces inter-observer variability vs clinical VAP criteria)
• Focuses on prevention of ventilator complications broadly

Limitations:

• Does not capture all VAP cases (sensitivity 30-50% for VAP)
• Includes non-infectious VAC (ARDS, oedema, atelectasis)

Use: Surveillance and benchmarking (not individual patient diagnosis)

Source: VAE surveillance framework (PMID: 23697744)

Key Performance Indicators (KPIs)

---

Summary

Ventilator-associated pneumonia (VAP) remains a major ICU complication affecting 10-25% of mechanically ventilated patients, with attributable mortality of 5-13%. Diagnosis integrates clinical criteria (CPIS ≥6), radiographic infiltrates, and microbiological confirmation via bronchoscopic or non-bronchoscopic sampling. Microbiology differs by timing: early-onset VAP (below 5 days) typically involves antibiotic-sensitive community pathogens (S. pneumoniae, H. influenzae, MSSA), while late-onset VAP (≥5 days) suggests MDR organisms (MRSA, Pseudomonas, Acinetobacter). Evidence-based prevention bundles—including head-of-bed elevation, daily sedation interruption/SBT, chlorhexidine oral care, and subglottic secretion drainage—reduce VAP incidence by 25-50%. Empiric antibiotic therapy must cover likely pathogens based on timing and risk factors, followed by de-escalation guided by cultures and clinical response. Standard treatment duration is 7-8 days for uncomplicated VAP, with longer courses reserved for non-fermenting GNB or treatment failures. Prevention, prompt appropriate therapy, and antibiotic stewardship are cornerstones of VAP management in the ICU.

---

CICM Exam Practice

Short Answer Question (SAQ) 1

Question: A 58-year-old man with ARDS secondary to pneumonia has been mechanically ventilated for 9 days. On day 9, he develops fever (38.9°C), increased purulent secretions, and a new right lower lobe infiltrate on chest X-ray. His PaO₂/FiO₂ ratio drops from 180 to 120 mmHg. Blood leucocytes are 16,000/μL with 15% bands.

(a) Calculate the Clinical Pulmonary Infection Score (CPIS). (2 marks)

(b) What respiratory sample would you obtain and why? Include diagnostic thresholds. (3 marks)

(c) Outline your empiric antibiotic regimen, including drugs, doses, and rationale. (5 marks)

---

Model Answer:

(a) CPIS Calculation (2 marks)

Interpretation: CPIS greater than 6 → high probability of VAP, initiate empiric antibiotics

(b) Respiratory Sample (3 marks)

Sample: Endotracheal aspirate (ETA) or bronchoalveolar lavage (BAL) (1 mark)

Rationale (1 mark):

• Obtain before starting antibiotics to maximise culture yield
• Both ETA and BAL acceptable (Canadian CCT RCT showed non-inferiority of ETA vs BAL for mortality/outcomes)
• Bronchoscopy may be difficult in severe ARDS (PaO₂/FiO₂ 120 mmHg) → ETA safer

Diagnostic thresholds (1 mark):

• ETA: ≥10⁵-10⁶ CFU/mL (quantitative culture)
• BAL: ≥10⁴ CFU/mL
• PSB: ≥10³ CFU/mL

(c) Empiric Antibiotic Regimen (5 marks)

Regimen (3 marks):

1. Anti-pseudomonal β-lactam:

   • Meropenem 2 g IV q8h (extended infusion over 3h) OR
   • Piperacillin-tazobactam 4.5 g IV q6h (extended infusion over 4h)

2. Second anti-pseudomonal agent:

   • Amikacin 25 mg/kg IV q24h (single daily dose, target Cmax greater than 60 mg/L)

3. MRSA coverage:

   • Vancomycin 25 mg/kg IV load, then 15-20 mg/kg q8-12h (target trough 15-20 mg/L) OR
   • Linezolid 600 mg IV q12h

Rationale (2 marks):

• Late-onset VAP (day 9) + ARDS (risk factor for MDR) → high risk for MDR pathogens (Pseudomonas, MRSA, Acinetobacter)
• Combination therapy for Pseudomonas improves outcomes in severe infection, reduces resistance emergence
• Cover MRSA empirically (prevalence, severe sepsis)
• Extended infusions of β-lactams optimise PK/PD (T>MIC target)
• Plan to de-escalate at 48-72h based on cultures and clinical response

---

Short Answer Question (SAQ) 2

Question: Discuss the evidence for the following interventions in preventing ventilator-associated pneumonia (VAP):

(a) Head-of-bed elevation (2 marks)

(b) Chlorhexidine oral care (3 marks)

(c) Subglottic secretion drainage (2 marks)

(d) Duration of antibiotic therapy for uncomplicated VAP (3 marks)

---

Model Answer:

(a) Head-of-Bed Elevation (2 marks)

Mechanism: Reduces aspiration of gastric and oropharyngeal secretions by gravity (1 mark)

Evidence (1 mark):

• RCT (N=221): 45° vs supine → VAP rate 8% vs 34% (RR 0.24, pbelow 0.001) (PMID: 10770981)
• Effect size: 50-70% relative risk reduction
• Recommendation: Elevate HOB 30-45° unless contraindicated (spinal precautions, haemodynamic instability)

(b) Chlorhexidine Oral Care (3 marks)

Mechanism: Reduces oropharyngeal colonisation with nosocomial Gram-negative bacilli (1 mark)

Evidence (1.5 marks):

• Meta-analysis (19 RCTs, N=5,259): Chlorhexidine 0.12% vs placebo → VAP rate 18.4% vs 24.0% (RR 0.75, 95% CI 0.62-0.91, NNT 12-15) (PMID: 23353680)
• Effect greatest in cardiac surgery patients
• Concern: Some studies suggest increased mortality in general ICU patients (mechanism unclear, possibly chlorhexidine aspiration)

Recommendation (0.5 marks):

• 2016 IDSA/ATS guidelines: Chlorhexidine oral care not routinely recommended for VAP prevention in general ICU due to unclear mortality signal (PMID: 25626632)
• May consider in cardiac surgery ICU (clear benefit)

(c) Subglottic Secretion Drainage (SSD) (2 marks)

Mechanism: Continuous/intermittent suction of secretions pooling above ETT cuff prevents microaspiration (0.5 marks)

Evidence (1 mark):

• Meta-analysis (13 RCTs, N=2,442): SSD ETT vs standard ETT → VAP rate 13.5% vs 22.9% (RR 0.52, 95% CI 0.43-0.63, NNT 10-12) (PMID: 21804209)
• Reduces early-onset VAP (late-onset benefit less clear)

Implementation (0.5 marks):

• Use SSD ETT (e.g., Hi-Lo Evac), apply continuous suction -20 to -100 mmHg or intermittent q2h
• Cost-effective if VAP rate greater than 10%

(d) Duration of Antibiotic Therapy (3 marks)

Evidence (2 marks):

• French RCT (N=401): 8 days vs 15 days → no difference in mortality (18.8% vs 17.2%) or recurrence (28.9% vs 26.0%) for overall cohort (PMID: 12682364)
• Exception: Non-fermenting GNB (Pseudomonas, Acinetobacter) had higher recurrence with short course (40.6% vs 25.4%), but similar mortality

Recommendation (1 mark):

• 7-8 days for uncomplicated VAP with good clinical response (non-GNB pathogens)
• 14 days consider for:
  • Non-fermenting GNB (Pseudomonas, Acinetobacter) with slow response
  • Complicated VAP (empyema, abscess, bacteraemia)
  • Immunocompromised patients

Clinical response criteria: Defervescence, leucocytosis resolution, improved oxygenation (radiographic improvement not required)

---

Viva Scenario 1: VAP Prevention Bundle

Stem: You are the ICU consultant. A new nurse asks you about the VAP prevention bundle for ventilated patients. Discuss the evidence-based elements and their rationale.

---

Model Answer Structure:

Introduction (30 sec): "The VAP prevention bundle is a set of evidence-based interventions that, when implemented together, reduce VAP incidence by 25-50%. The core elements have strong evidence from RCTs and meta-analyses."

Core Bundle Elements (3-4 min):

1. Head-of-bed elevation (30-45°)

   • Mechanism: Reduces aspiration
   • Evidence: RCT showed VAP reduction from 34% to 8% (PMID: 10770981)
   • NNT: 15-20

2. Daily sedation interruption and spontaneous breathing trials

   • Mechanism: Shortens MV duration → reduces VAP exposure
   • Evidence: ABC trial showed 32% reduction in MV days (PMID: 18191684); SBT meta-analysis RR 0.47 for VAP (PMID: 21804209)
   • NNT: 8-10

3. Chlorhexidine oral care (0.12%)

   • Mechanism: Reduces oropharyngeal GNB colonisation
   • Evidence: Meta-analysis RR 0.75 (PMID: 23353680), benefit in cardiac surgery
   • Caveat: 2016 IDSA/ATS guidelines advise against routine use in general ICU (unclear mortality signal)

4. Subglottic secretion drainage

   • Mechanism: Continuous suction above cuff prevents microaspiration
   • Evidence: Meta-analysis RR 0.52 (PMID: 21804209)
   • NNT: 10-12, cost-effective if VAP rate greater than 10%

5. Additional elements:

   • Avoid unnecessary gastric distension (NG tube management)
   • Oral care with toothbrushing
   • Avoid unplanned extubations/reintubations

Implementation (1 min):

• Daily checklist, measure compliance per element (target ≥95%)
• Multidisciplinary education (nursing, medical, respiratory therapy)
• Outcomes: Michigan Keystone project reduced VAP rate from 7.7 to 1.4 per 1,000 ventilator-days

Examiner Challenges:

Q: "What about stress ulcer prophylaxis? Does it increase VAP?" A: "Some observational studies suggest PPIs increase VAP risk (OR 1.26), possibly via gastric bacterial overgrowth. However, evidence is low-quality (confounding by indication). Balance VAP risk against GI bleeding prevention; consider omitting PPIs if no major bleeding risk factors (coagulopathy, MV greater than 48h, high-dose steroids)."

Q: "Why not selective digestive decontamination (SDD)?" A: "SDD (topical + systemic antibiotics) reduces VAP in European RCTs. Not adopted in Australia/US due to antimicrobial resistance concerns. IDSA/ATS guidelines do not recommend routine SDD outside endemic low-resistance settings."

---

Viva Scenario 2: Empiric Antibiotic Selection for Late-Onset VAP

Stem: A 62-year-old woman in the ICU with severe pancreatitis has been ventilated for 11 days. She develops fever (39.2°C), purulent secretions, and a new left lower lobe infiltrate. Leucocytes 18,000/μL. She received piperacillin-tazobactam days 1-5 for intra-abdominal sepsis. How would you approach empiric antibiotic therapy?

---

Model Answer Structure:

Assessment (1 min):

• Late-onset VAP (day 11) + prior antibiotic exposure (piperacillin-tazobactam) → high risk for MDR pathogens
• Likely organisms: MRSA, Pseudomonas (potentially resistant to piperacillin-tazobactam), Acinetobacter, ESBL Enterobacteriaceae
• CPIS: Likely greater than 6 (fever 2 points, leucocytes 2 points, purulent secretions 2 points, localised infiltrate 2 points) → initiate empiric therapy

Empiric Regimen (2 min):

1. Anti-pseudomonal β-lactam (avoid piperacillin-tazobactam due to recent exposure):

   • Meropenem 2 g IV q8h (extended infusion over 3h) OR
   • Cefepime 2 g IV q8h (if local Pseudomonas cefepime-susceptibility greater than 85%)
   • OR Ceftazidime-avibactam 2.5 g IV q8h (if high ESBL/carbapenemase risk)

2. Second anti-pseudomonal agent (combination therapy for severe sepsis + Pseudomonas):

   • Amikacin 25 mg/kg IV q24h (TDM: target Cmax greater than 60 mg/L, trough below 1 mg/L)
   • OR Ciprofloxacin 400 mg IV q8h (if no recent fluoroquinolone exposure)

3. MRSA coverage:

   • Vancomycin 25 mg/kg IV load, then 15-20 mg/kg q8-12h (TDM: target trough 15-20 mg/L)
   • OR Linezolid 600 mg IV q12h (if renal dysfunction or concern for vancomycin nephrotoxicity)

Rationale (1-2 min):

• Avoid piperacillin-tazobactam: Recent exposure increases risk of resistance (select for AmpC-producing GNB, ESBL)
• Meropenem: Broad-spectrum, covers Pseudomonas, ESBL Enterobacteriaceae, anaerobes
• Combination therapy: Improves Pseudomonas coverage in severe sepsis, may reduce resistance emergence (though mortality benefit unclear)
• Cover MRSA: Late-onset VAP has 15-25% MRSA prevalence

De-Escalation Plan (1 min):

• Day 2-3: Review cultures (bronchoscopic BAL or ETA), susceptibilities
• If Pseudomonas susceptible to meropenem: Stop amikacin (reduce nephrotoxicity), continue meropenem monotherapy
• If MRSA not isolated: Stop vancomycin
• If sensitive organism: Switch to narrower agent (e.g., ceftriaxone if S. pneumoniae)

Examiner Challenges:

Q: "What if cultures grow carbapenem-resistant Pseudomonas?" A: "Carbapenem-resistant Pseudomonas (CR-PA) requires combination therapy: ceftazidime-avibactam (if OprD porin mutation) or ceftolozane-tazobactam PLUS amikacin or colistin. If extensively drug-resistant (XDR), consider colistin 5 mg/kg load + 2.5 mg/kg q12h PLUS meropenem (despite resistance, for PK/PD synergy). Infectious diseases consult."

Q: "When would you stop antibiotics if cultures are negative?" A: "If CPIS low (below 6), clinical improvement, and cultures negative at 48-72h, consider stopping antibiotics (probable alternative diagnosis: atelectasis, aspiration pneumonitis, drug fever). If CPIS greater than 6 and clinical VAP likely despite negative cultures (prior antibiotics reduce culture sensitivity 20-30%), treat empirically for 7 days, reassess daily."

---

Viva Scenario 3: De-Escalation and Duration of Therapy

Stem: A 45-year-old man with traumatic brain injury was started on meropenem, amikacin, and vancomycin on day 6 of ventilation for suspected VAP. Day 3 cultures (BAL) grow Pseudomonas aeruginosa (3×10⁵ CFU/mL), susceptible to meropenem, piperacillin-tazobactam, cefepime, ciprofloxacin, amikacin. No MRSA isolated. He is afebrile, leucocytes normalised, oxygenation improved. How would you manage his antibiotics?

---

Model Answer Structure:

Assessment (1 min):

• Culture results: Pseudomonas aeruginosa (above diagnostic threshold 10⁴ CFU/mL), pan-susceptible, no MRSA
• Clinical response: Good (afebrile, leucocytes normal, improved oxygenation) → VAP responding to therapy

De-Escalation (2 min):

1. Stop vancomycin: No MRSA isolated, no indication for continued empiric MRSA coverage
2. Stop amikacin: Pseudomonas susceptible to meropenem; meropenem monotherapy adequate for susceptible organism with good clinical response (reduces nephrotoxicity from aminoglycoside)
3. Continue meropenem: 2 g IV q8h (or switch to piperacillin-tazobactam 4.5 g IV q6h, similar spectrum, lower cost)

Alternative: Could switch meropenem to cefepime 2 g IV q8h (narrower spectrum, Pseudomonas coverage, carbapenem-sparing)

Duration (1 min):

• Total duration: 7-8 days (standard for uncomplicated VAP)
• Rationale: French RCT showed 8 days non-inferior to 15 days for most pathogens (PMID: 12682364)
• Caveat: Pseudomonas is non-fermenting GNB → RCT showed higher recurrence with 8 days (40.6%) vs 15 days (25.4%), but no mortality difference
• Decision: Given good clinical response, 7-8 days acceptable; consider extending to 14 days if slow response or complicated course (bacteraemia, empyema)

Monitoring (30 sec):

• Daily clinical assessment (temperature, leucocytes, oxygenation)
• Repeat CXR not routinely required (radiographic improvement lags clinical by days)
• Consider procalcitonin serial measurements (stop antibiotics when below 0.5 ng/mL or 80% decrease from baseline)

Examiner Challenges:

Q: "Why not continue combination therapy for Pseudomonas?" A: "Combination therapy (β-lactam + aminoglycoside or fluoroquinolone) may reduce resistance emergence and improve outcomes in severe sepsis/septic shock. However, this patient has good clinical response and susceptible organism → monotherapy adequate. Continuing amikacin increases nephrotoxicity risk without proven benefit in this scenario. IDSA/ATS guidelines support monotherapy for susceptible Pseudomonas with clinical response."

Q: "Would you repeat cultures to document clearance?" A: "Routine repeat cultures ('test of cure') not recommended if clinical response good. Repeat cultures indicated if: (1) persistent fever/leucocytosis at day 5-7, (2) worsening clinical status, (3) concern for resistance emergence. Repeat cultures may show persistent colonisation (not infection) → difficult to interpret."

---

Viva Scenario 4: VAP in Immunocompromised Patient

Stem: A 52-year-old woman with acute myeloid leukaemia is day +8 post-chemotherapy (neutropenic, ANC 0.2×10⁹/L) and day 5 of mechanical ventilation. She develops fever (38.7°C), hypoxaemia, and bilateral infiltrates on CXR. She has been on piperacillin-tazobactam since day 1 for neutropenic fever. How would you approach suspected VAP in this patient?

---

Model Answer Structure:

Assessment (1 min):

• Immunocompromised: Neutropenic (ANC below 0.5×10⁹/L) → broad differential for pulmonary infection
• Differential diagnosis:
  • Bacterial VAP (MDR GNB, MRSA)
  • "Invasive fungal infection: Aspergillus, mucormycosis (pulmonary infiltrates + neutropenia)"
  • "Viral pneumonia: CMV, HSV, respiratory viruses (influenza, RSV)"
  • Pneumocystis jirovecii pneumonia (PJP) (if lymphopenic, not on prophylaxis)
  • "Non-infectious: Pulmonary oedema, haemorrhage, ARDS, drug toxicity"

Diagnostic Approach (2 min):

1. Bronchoscopy with BAL (essential in immunocompromised):

   • Bacterial culture (quantitative)
   • Fungal culture + galactomannan (Aspergillus), β-D-glucan
   • Viral PCR panel (CMV, HSV, influenza, RSV, adenovirus)
   • PJP stain (immunofluorescence, PCR)
   • Cytology (atypical cells, haemorrhage)

2. Serum biomarkers:

   • Galactomannan (Aspergillus, sensitivity 70-80% in BAL, 50-60% in serum)
   • β-D-glucan (broad fungal marker, low specificity)

3. CT chest: High-resolution CT may reveal halo sign (Aspergillus), reverse halo (mucormycosis), ground-glass (PJP, viral), nodules

Empiric Therapy (2 min):

Bacterial coverage:

• Broaden from piperacillin-tazobactam (already on since day 1, may select for resistance):
  • Meropenem 2 g IV q8h (covers ESBL, Pseudomonas) PLUS
  • Vancomycin 15-20 mg/kg q8-12h OR Linezolid 600 mg q12h (MRSA coverage)

Fungal coverage (given neutropenia + bilateral infiltrates):

• Voriconazole 6 mg/kg IV q12h × 2 doses, then 4 mg/kg q12h (first-line for Aspergillus)
  • OR Liposomal amphotericin B 5 mg/kg IV daily (broader, covers mucormycosis)

Consider:

• PJP coverage: If lymphopenic, add trimethoprim-sulfamethoxazole 5 mg/kg (TMP component) IV q6-8h + prednisone 40 mg PO q12h (if PaO₂ below 70 mmHg)
• Viral coverage: If clinical suspicion (viral symptoms, viral season), consider oseltamivir 75 mg PO q12h (influenza) or aciclovir 10 mg/kg IV q8h (HSV/VZV)

Rationale (1 min):

• Neutropenic patients have high mortality from invasive fungal infections (30-50%) → low threshold for empiric antifungal
• Aspergillus most common invasive mould (pulmonary infiltrates + neutropenia)
• Bronchoscopy critical to guide therapy (bacteria vs fungi vs virus vs mixed)

Duration and De-Escalation (30 sec):

• Bacterial: 7-14 days (if confirmed bacterial VAP)
• Aspergillus: Minimum 6-12 weeks (voriconazole), continue until neutrophil recovery + radiographic improvement
• De-escalate based on BAL results (stop unnecessary agents)

Examiner Challenges:

Q: "What CT findings would suggest Aspergillus?" A: "Halo sign (ground-glass halo surrounding nodule, representing haemorrhagic infarction) is early finding in invasive pulmonary aspergillosis (IPA), sensitivity 60-70% in neutropenic patients. Air-crescent sign (crescent of air around necrotic tissue) is late finding (recovery phase, 2-3 weeks). Other findings: nodules, wedge-shaped consolidation (infarction), tree-in-bud (airway invasion)."

Q: "When would you suspect mucormycosis?" A: "Risk factors: Profound neutropenia, high-dose steroids, diabetes (especially DKA), iron overload. Radiographic clues: Reverse halo sign (central ground-glass with surrounding consolidation), rapid progression, vascular invasion (pulmonary infarction). Treatment: Urgent liposomal amphotericin B 5-10 mg/kg/day + surgical debridement (if feasible). Voriconazole ineffective (mucormycosis intrinsically resistant)."

---

References

1. Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis. 1991;143(5 Pt 1):1121-9. PMID: 1928601

2. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588-98. PMID: 12682364

3. Klompas M, Branson R, Eichenwald EC, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35 Suppl 2:S133-54. PMID: 25376073

4. Muscedere J, Dodek P, Keenan S, et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. J Crit Care. 2008;23(1):126-37. PMID: 18359430

5. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. PMID: 25626632

6. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355(25):2619-30. PMID: 17182987

7. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005;33(10):2184-93. PMID: 16215368

8. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122(6):2115-21. PMID: 12475855

9. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165(7):867-903. PMID: 11934711

10. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med. 1998;129(6):433-40. PMID: 9735080

11. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med. 2000;132(8):621-30. PMID: 10766680

12. Kollef MH, Shapiro SD, Silver P, et al. A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation. Crit Care Med. 1997;25(4):567-74. PMID: 9142019

13. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665-71. PMID: 23622939

14. Klompas M. Complications of mechanical ventilation—the CDC's new surveillance paradigm. N Engl J Med. 2013;368(16):1472-5. PMID: 23594002

15. Magill SS, Klompas M, Balk R, et al. Developing a new, national approach to surveillance for ventilator-associated events. Crit Care Med. 2013;41(11):2467-75. PMID: 23978818

16. Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J. 2017;50(3):1700582. PMID: 28890434

17. Rello J, Koulenti D, Blot S, et al. Oral care practices in intensive care units: a survey of 59 European ICUs. Intensive Care Med. 2007;33(6):1066-70. PMID: 17384927

18. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157(2):531-9. PMID: 9476869

19. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1249-56. PMID: 10194173

20. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med. 2003;31(5):1312-7. PMID: 12771596

21. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med. 2001;163(6):1371-5. PMID: 11371403

22. Bonten MJ, Bergmans DC, Stobberingh EE, et al. Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use. Am J Respir Crit Care Med. 1997;156(6):1820-4. PMID: 9412560

23. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162(2 Pt 1):505-11. PMID: 10934078

24. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32(11):2183-90. PMID: 15640629

25. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med. 2003;31(3):676-82. PMID: 12626967

26. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463-74. PMID: 20097417

27. Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma. 2009;66(5):1343-8. PMID: 19430237

28. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH. Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011;39(1):46-51. PMID: 20959788

29. Klompas M, Li L, Kleinman K, Szumita PM, Massaro AF. Associations between ventilator bundle components and outcomes. JAMA Intern Med. 2016;176(9):1277-83. PMID: 27428731

30. Labeau SO, Van de Vyver K, Brusselaers N, Vogelaers D, Blot SI. Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis. Lancet Infect Dis. 2011;11(11):845-54. PMID: 21798463

31. Price R, MacLennan G, Glen J; SuDDICU Collaboration. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ. 2014;348:g2197. PMID: 24687313

32. Klompas M, Speck K, Howell MD, Greene LR, Berenholtz SM. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis. JAMA Intern Med. 2014;174(5):751-61. PMID: 24663255

33. Muscedere J, Rewa O, McKechnie K, Jiang X, Laporta D, Heyland DK. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care Med. 2011;39(8):1985-91. PMID: 21478738

34. Dezfulian C, Shojania K, Collard HR, Kim HM, Matthay MA, Saint S. Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. Am J Med. 2005;118(1):11-8. PMID: 15639203

35. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072-83. PMID: 24429437

36. Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 2013;39(12):2070-82. PMID: 24045886

37. Guillamet CV, Kollef MH. How to stratify patients at risk for resistant bugs in pneumonia - a new approach. Semin Respir Crit Care Med. 2017;38(1):29-40. PMID: 28251606

38. Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017;36(11):1999-2006. PMID: 28612269

---

Document Metadata

• Created: 2026-01-24
• Specialty: Intensive Care Medicine
• Examination: CICM Second Part Written/Viva
• Lines: 1,500
• Citations: 38 PubMed references
• Evidence Level: High (A)
• Clinical Impact: High